STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: STI571 may interfere with the growth of cancer cells and may be effective
treatment for chronic myelogenous leukemia.
PURPOSE: Phase II trial to study the effectiveness of STI571 in treating patients who have
accelerated phase chronic myelogenous leukemia.